An Evaluation of Cultured Milk Drink on Immune Status of Patients With Irritable Bowel Syndrome: Constipation Predominant
- Conditions
- Irritable Bowel Syndrome With Constipation
- Interventions
- Dietary Supplement: Cultured milk drink
- Registration Number
- NCT04647045
- Lead Sponsor
- National University of Malaysia
- Brief Summary
Our previous work on the use of probiotics improved the clinical symptoms in irritable bowel syndrome with constipation-predominant. This study would like to explore further use of probiotics in the immune system of the patients with irritable bowel syndrome.
- Detailed Description
This is a case control study involving participants who fulfilled the Rome III criteria for constipation-predominant irritable bowel syndrome. The patients were recruited from the Gastroenterology clinic at Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur. A total of 165 participants were recruited based on probability (power) of 0.8 and Type I error was set at 0.05.
The investigators included healthy participants above 18 years old. Those less than 18 years old; constipation due to other medical illnesses such as diabetes mellitus, inflammatory bowel disease, hypothyroidism, colorectal cancer, neurological diseases, major depression, lactose intolerance, pregnancy, breastfeeding women and must not be on chronic opioids or anti- depressants were excluded. Participants must not consume any antibiotics, probiotic, prebiotic, symbiotic and/or laxatives less than two weeks before recruitment.
Participants were required to consume three bottles of 125 ml cultured milk drink daily for 30 days. Each bottle contains 10\^9 cfu Lactobacillus acidophilus LA-5 and Lactobacillus paracasei L. CASEI-01. In each 100 ml unit, it contains 4.06 g of fructose, 4.14 g of glucose, 0.29 g of sucrose, less than 0.1 g of maltose and 1.35 g of lactose. Cold chain was maintained below 10°C during storage, transportation and distribution. Prior to consumption of the cultured milk drinks, fecal and blood samples from the participants were obtained to determine their baseline fecal pH and serum cytokines level respectively. Each of the participants answered a food frequency questionnaire to assess their dietary profile (data are not presented in this paper) and the Garrigues Questionnaire to evaluate their clinical symptoms and physical activity. The same parameters were taken following 30 days of cultured milk drinks' consumption.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 165
- Do not fulfil the Rome III criteria for irritable bowel syndrome
- constipation due to other medical illnesses such as diabetes mellitus, inflammatory bowel disease, hypothyroidism, colorectal cancer, neurological diseases, major depression, lactose intolerance, pregnancy, breastfeeding women and must not be on chronic opioids or anti- depressants. Participants must not consume any antibiotics, probiotic, prebiotic, symbiotic and/or laxatives less than two weeks before recruitment.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description IBS-C group Cultured milk drink 77 constipation-predominant IBS were given three bottles of 125 ml cultured milk drink daily for 30 days Non-IBS group Cultured milk drink 88 non-IBS subjects (healthy individuals) were given similar probiotics for 30 days.
- Primary Outcome Measures
Name Time Method Serum cytokine level 30 days Serum cytokine was determined using ELISA method at day 0 and day 30.
- Secondary Outcome Measures
Name Time Method Intestinal transit time 30 days Intestinal transit time was determined using red carmine capsule prior to the consumption of probiotics.
Fecal pH 30 days Litmus pH paper was used to determine fecal pH at day 0 and day 30
Constipation related symptoms 30 days Garrigues Questionnaire was used to assess the symptoms at day 0 and day 30. The questions are asked to each participant in the form of 'yes' or 'no'. The symptoms are straining during defecation, passing hard stool, number of bowel movements per week and incomplete emptying sensation after bowel movement. The results were reported as % of patients having the listed symptoms at pre- and post-intervention.
Trial Locations
- Locations (1)
Norfilza M Mokhtar
🇲🇾Kuala Lumpur, Wilayah Persekutuan, Malaysia